CRMD CorMedix Inc

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                   
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * ARMSTRONG JR. JOHN L.	2. Issuer Name and Ticker or Trading Symbol CorMedix Inc. [ CRMD ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) Exec VP of Tech Operations
(Last)          (First)          (Middle) C/O CORMEDIX INC., 400 CONNELL DRIVE, SUITE 5000	3. Date of Earliest Transaction (MM/DD/YYYY) 5/11/2020
(Street) BERKELEY HEIGHTS, NJ 07922 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								69378.0000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy Common Stock)	$5.6300	5/11/2020		A		37500.0000		(1)	5/11/2030	Common Stock	37500.0000	$5.6300	37500.0000	D
Stock Option (Right to Buy Common Stock)	$4.0800	5/11/2020		A		37500.0000		(1)	5/11/2030	Common Stock	37500.0000	$4.0800	37500.0000	D
Stock Option (Right to Buy Common Stock)	$5.6300							(2)	2/25/2030	Common Stock	24764.0000		24764.0000	D
Stock Option (Right to Buy Common Stock)	$8.3000							(3)	1/10/2029	Common Stock	7830.0000		7830.0000	D
Stock Option (Right to Buy Common Stock)	$10.9000							(4)	3/1/2027	Common Stock	13400.0000		13400.0000	D
Stock Option (Right to Buy Common Stock)	$7.6000							(5)	11/14/2024	Common Stock	2000.0000		2000.0000	D
Stock Option (Right to Buy Common Stock)	$16.2500							(6)	7/28/2025	Common Stock	3000.0000		3000.0000	D
Stock Option (Right to Buy Common Stock)	$12.5500							(7)	3/8/2026	Common Stock	40000.0000		40000.0000	D

Explanation of Responses:
(1)	These options were granted on 05/11/2020. These options vest 1/4 on the date of grant, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant.
(2)	These options were granted on 02/25/2020. These options vest 1/4 on the date of grant, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant.
(3)	These options were granted on 1/10/2019. These options vest, subject to continued employment, as follows: 35% of the options vest over time, with 25% vested on the grant date and 25% vesting on the first, second and third anniversaries of the grant date; and 65% of the options vest upon the achievement of certain milestones. These options include options to purchase an aggregate of 1,575 shares that are subject to vesting 50% on January 10, 2021 and 50% on January 10, 2022.
(4)	The option vests based on certain performance milestones. The option will be forfeited if such milestones are not met by certain dates. These options include options to purchase 6,800 shares that are subject to the achievement of certain milestones.
(5)	These options vested upon the achievement of certain milestones, subject to continued employment.
(6)	One third of these options vested upon the achievement of a certain milestone and one third vested on each of December 31, 2015 and July 28, 2015.
(7)	15,000 of these options vested monthly over four years, beginning on March 9, 2016, 20,000 vest upon the achievement of a certain milestone, subject to continued employment, and the rest vested upon the achievement of certain milestones.

Remarks: The Issuer effected a 1-for-5 reverse stock split of its common stock on March 26, 2019. All share and per share exercise price amounts shown in this Form 4 have been adjusted to reflect the reverse stock split.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
ARMSTRONG JR. JOHN L. C/O CORMEDIX INC. 400 CONNELL DRIVE, SUITE 5000 BERKELEY HEIGHTS, NJ 07922			Exec VP of Tech Operations

Signatures
/s/ John L. Armstrong Jr.		5/13/2020
**Signature of Reporting Person		Date